FluoGuide develops surgical solutions that are expected to reduce suffering for the patient and increase the likelihood of cure as well as reducing costs for the health care system.

New exchange: Nasdaq First North

FluoGuide is moving from Spotlight to Nasdaq First North. Shareholders are strongly encouraged to make sure they will be able to freely trade their shares in the future.

New exchange: Nasdaq First North


Morten Albrechtsen - CEO (Chief Executive Officer) FluoGuide

Morten Albrechtsen

CEO (Chief Executive Officer)

Morten Albrechtsen is an MD and BBA (‘HD’ in marketing, CBS). Morten is a seasoned entrepreneur with a strong medical, commercial and financial background. The expertise is gained within a broad range of therapeutic areas and with both drugs and devices. The development expertise includes all stages, pre-clinical, clinical and post-market development, and with various disciplines. The commercial expertise is gained internationally and includes sales through partners, affiliates and direct to patients, hospitals and direct to end-users. It also includes business development with licensing and corporate deals. Previously, Morten has developed and launched new health care products and concepts internationally, e.g. in Nycomed Pharma, now Takeda Pharmaceuticals Ltd. (pain control), Nanovi (brought a new cancer product to the market in Europe and prepared it for US) and Boehringer Ingelheim GmbH (hospital sales, cardiovascular, stroke female health and pain control). Morten has also a strong experience from early clinical development in e.g. Enkam A/S (CNS drug development including medicines for Alzheimer’s disease, Parkinson’s disease and depression) and several others.

Number of FluoGuide shares 1,488,610 and 100,000 warrants (Partly owned via Wexotec ApS)

Henrik Moltke - CFO FluoGuide

Henrik Moltke


Henrik Moltke holds an MSc (Econ) in strategy and international economics and has more than 30 years of experience from life sciences and health care sectors, with roles such as CFO and Senior Vice President. The primary focus of his career has been venture financing, including IPOs and follow on capital increases in the public markets, investor relations, business development, finance planning and strategic development.­ Zoetis (acquired Scandinavian Micro Biodevices- SMB), Astion Pharma, NeuroSearch.

Number of FluoGuide shares 1,216 and 30,300 warrants

Andreas Kjaer - Head of Scientific Advisory board FluoGuide

Andreas Kjaer

Head of Scientific Advisory board

Andreas Kjaer, is an MD, PhD, DMSc and professor at the University of Copenhagen and chief physician at Rigshospitalet, the National University Hospital of Denmark. His research is focused on molecular imaging with PET, PET/MRI and OPTICAL IMAGING in cancer and cardiovascular disease and his achievements include development of several new tracers that have reached first-in-humans clinical use. He is the holder of an ERC Advanced Grant, has published more than 400 peer-review articles and has received numerous prestigious scientific awards over the years. Andreas Kjaer also has an MBA from Copenhagen Business School.

Number of FluoGuide shares  2,126,107 and 100,000 warrants (Partly owned via Life Science IVS)

Grethe Nørskov Rasmussen - CDO (Chief Development officer) FluoGuide

Grethe Nørskov Rasmussen

CDO (Chief Development officer)

Grethe Nørskov Rasmussen holds an M.Sc and PhD. Grethe Rasmussen is an experienced product developer with a profound understanding of CMC and former Senior Vice President Product Development at Ascendis Pharma A/S, where Rasmussen worked for over 10 years. Previously, Grethe Rasmussen served as Vice President for Protein Science at Maxygen, Inc. and later as Managing Director for the Danish subsidiary of Maxygen. Prior to joining Maxygen, Dr. Rasmussen held various positions at Novo Nordisk A/S, a global healthcare company, where she contributed to research and development. Dr. Rasmussen holds a PhD in Biochemistry from the Danish Technical University.

Number of FluoGuide shares 373,185 and 25,000 warrants

Dorthe Grønnegaard Mejer - VP Clinical Development FluoGuide

Dorthe Grønnegaard Mejer

VP Clinical Development

Dorthe Grønnegaard Mejer has a M.Sc. in Pharmaceutical Sciences from Copenhagen University. She has previously held several positions across different clinical development disciplines as well as positions within clinical oncology development in other biotech companies such as Genmab, Larix, Orphazyme and Oncology Venture.

Number of FluoGuide shares 3,241 and 15,300 warrants